Myomo, Inc.

  • Market Cap: Micro Cap
  • Industry: Retailing
  • ISIN: US62857J2015
USD
1.02
0.06 (6.02%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Myomo, Inc. stock-summary
stock-summary
Myomo, Inc.
Retailing
Myomo, Inc. is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke. Its MyoPro myoelectric limb orthosis is a powered brace that supports a weakened and deformed arm for functional use. The MyoPro is an elbow/wrist/Hand orthosis, which supports the arm and helps to bend and straighten the arm at the elbow. The brace provides assistive function for joint motion that enables a user to self-initiate and control movements of a partially paralyzed arm using their own muscle signals. When the user tries to bend their arm, sensors in the brace detect the weak muscle signal, which activates the motor to amplify their weak muscle signal to help bend and move their arm. The brace uses non-invasive skin sensors.
Company Coordinates stock-summary
Company Details
ONE BROADWAY, 14TH FLOOR , CAMBRIDGE MA : 02142
stock-summary
Tel: 1 617 9969058
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 10 Schemes (6.31%)

Foreign Institutions

Held by 24 Foreign Institutions (10.76%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Steve Kelly
Founder, Chairman of the Board, President and Chief Operating Officer
Mr. Paul Gudonis
Chief Executive Officer, Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
10 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summary
Industry

Retailing

stock-summary
Market cap

USD 38 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.63

stock-summary
Return on Equity

-52.93%

stock-summary
Price to Book

2.13